45.13 0.00 (0.00%)
After hours: 4:24PM EDT
|Bid||44.80 x 900|
|Ask||45.89 x 800|
|Day's Range||44.52 - 45.82|
|52 Week Range||39.07 - 65.51|
|Beta (3Y Monthly)||3.47|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Short interest is moderate for IONS with between 5 and 10% of shares outstanding currently on loan. The net inflows of $2.94 billion over the last one-month into ETFs that hold IONS are not among the highest of the last year and have been slowing.
The stock recovered from a surprising rejection at the end of August, but has tumbled once again in the first half of October.
AG in a deal that could be worth up to $760 million for Ionis. As part of the deal to develop a drug called IONIS-FB-L(Rx) for the treatment of a wide range of diseases, Ionis will get a $75 million upfront payment and will then be eligible to receive up to $684 million in development, regulatory and sales milestone payments and license fees. Ionis is responsible for conducting a Phase 2 study, slated to begin in early 2019, in patients suffering from age-related macular degeneration -- the leading cause of blindness in the U.S. and developed countries -- and exploring the drug in a rare severe renal indication.
Shares of Ionis Pharmaceuticals Inc. rallied 4.7% in premarket trade, after the drug discovery company announced a new collaboration deal with Switzerland-based Roche Holding AG , which could be worth up to $759 million for Ionis. As part of the deal to develop IONIS-FB-L (Rx) for the treatment of complement-mediated diseases, Ionis will receive a $75 million upfront payment, and will be eligible for up to $684 million in milestone payments and license fees. Ionis is responsible for conducting a phase 2 trial of IONIS-FB-L for treating dry age-related macular degeneration (AMD) and for exploring the drug in a rare severe renal indication. Roche has the option to license the drug after the studies are completed. Ionis shares have shed 10.8% year to date through Tuesday, while the S&P 500 has gained 7.7%.
Ionis Pharmaceuticals generated second-quarter revenues of $118.0 million compared to $122.3 million in the second quarter of 2017, which reflected ~15.0% YoY (year-over-year) growth. In the first half, Ionis Pharmaceuticals reported revenues of $262.2 million, compared to $228.1 million in the first half of 2017.
On October 4, Ionis Pharmaceuticals (IONS) stock closed at $47.48, which is an ~1.06% decline from its closing price of $51.58 on October 3. Ionis Pharmaceuticals’ October 4 closing stock price was ~38.0% below its 52-week high of $65.51. This reflects an 11.0% increase in September. Ionis Pharmaceuticals stock hit its 52-week low of $39.07 on May 8.
After having one of its drugs rejected by the FDA in August, Cambridge biotech Akcea Therapeutics Inc. turned the tide on Friday, receiving approval for another treatment for a rare genetic disease. The FDA approved Tegsedi, known generically as inotersen, an RNA-based drug that is designed to treat a rare and often fatal genetic disease called hereditary ATTR amyloidosis, or hATTR amyloidosis. According to Akcea (Nasdaq: AKCA), the drug works by slowing down production of a protein that can build up and impede nervous system and organ functions.
Akcea Therapeutics Inc said on Friday its treatment, developed along with Ionis Pharmaceuticals , which targets a rare genetic disease was approved by the U.S. Food and Drug Administration. Akcea's once-weekly injection, Tegsedi, treats hereditary ATTR amyloidosis patients with polyneuropathy. Polyneuropathy, a symptom of the disease, is the simultaneous malfunction of peripheral nerves in the body resulting in tingling, numbness and kidney dysfunction.
Ionis Pharmaceuticals’ (IONS) revenue stream is segregated into two segments: Research and Development revenues from the collaborative agreements with other companies, and Commercial Revenues. Commercial Revenues include licensing and royalty revenues and Spinraza royalties. The chart below compares the revenues for Ionis Pharmaceuticals since the first quarter of 2017.
Ionis Pharmaceuticals (IONS), a leading biopharmaceutical company, has developed a variety of drugs for the treatment of life-threatening diseases through its broadly applicable drug discovery platform. Ionis reported earnings per share of -$0.29 on revenues of $117.7 million during the second quarter, reporting year-over-year growth of 5.0% during the quarter. The chart below compares the company’s revenues since the first quarter of 2017.
Ionis Pharmaceuticals (IONS) develops drugs for life-threatening diseases, and it commercializes the approved products in collaboration with other pharmaceutical companies. Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in YoY (year-over-year) revenues compared to the second quarter of 2017.
Ionis Pharmaceuticals Inc’s (NASDAQ:IONS): Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. With the latest financial year loss of -US$6.0m and a trailing-twelve month of -US$50.4m, the US$7.07b market-cap amplifies Read More...
Sarepta Therapeutics (SRPT) incurred a net loss of $109.27 million in the second quarter of 2018 compared to a net loss of $63.05 million in Q2 2017. Its net loss per share was $1.15 in the second quarter of 2017. Despite the surge in revenues, Sarepta’s net loss widened due to higher operating expenses, which increased from $98.35 million in the second quarter of 2017 to $176.96 million in the second quarter of 2018.
In the second quarter, Spectrum Pharmaceuticals (SPPI) generated net revenues of $24.2 million compared to $34.3 million in Q2 2017. In the first half of the year, Spectrum Pharmaceuticals reported net revenues of $54.7 million compared to $63.4 million in H1 2017.
Today, Arrowhead Pharmaceuticals (ARWR) stock is trading at $20.12, which represents ~42.7% growth from yesterday’s close of $14.10. Arrowhead Pharmaceuticals also hit its 52-week high of $22.39 today.
DSW (NYSE:DSW) jumped more than 20% on a surprisingly strong second-quarter report, while Ionis Pharmaceuticals (NASDAQ:IONS) fell nearly 16% on word that the FDA decided not to approve a drug very similar to the company’s Tegsedi, in trials right now. Stocks charts of Hewlett Packard Enterprise (NYSE:HPE), PG&E (NYSE:PCG) and PepsiCo (NASDAQ:PEP) are the most enticing setups. If the name PG&E rings a bell, it may be because it was featured as one of the top three stock charts back on Aug. 17.
Portola Pharmaceuticals (PTLA) reported net revenues of $4.0 million in the second quarter. PTLA posted net revenues of $3.8 million in the second quarter of 2017, reflecting ~6.0% YoY (year-over-year) growth. In the first half, Portola Pharmaceuticals reported net revenues of $10.7 million, compared to $8.9 billion in the first half of 2017.